SCYNEXIS Stock

SCYNEXIS Financing Cash Flow

The Net Financing Cash Flow of SCYNEXIS (SCYX) as of Aug 12, 2026 is -139,000.00 USD. In the previous year, Net Financing Cash Flow was -36.72 M USD — a change of -99.62% (higher).

Financing Cash Flow

-139,000.00USD

YoY

-99.62%

Last updated:

Net Financing Cash Flow of SCYNEXIS is 2026 -139,000.00 USD. Net Financing Cash Flow of SCYNEXIS was 2025 -36.72 M USD. It decreases by -99.62% higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Net Financing Cash Flow of SCYNEXIS is -139,000.00 USD in 2026.

Net Financing Cash Flow of SCYNEXIS changed from -36.72 M USD to -139,000.00 USD, representing a -99.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Cash Flow — SCYNEXIS

All Key Metrics — SCYNEXIS